A glazed-tile research panel ~ the mitochondrial peptide
MOTS-c peptide is a 16-amino-acid mitochondrial signal that activates AMPK and was higher in exercising muscle.
A scholarly digest of the metabolic and exercise-mimetic literature on the mitochondrial-derived peptide MOTS-c — every quantitative finding tiled to the study that measured it.
The short version
MOTS-c peptide is a tiny protein — 16 amino acids — that your own mitochondria make. (Mitochondria are the cell's power plants; this peptide is one of the few they encode themselves.) In mice and cells it switches on AMPK, a fuel-gauge enzyme that tells a cell to burn glucose and make energy. When researchers gave it to mice, it blunted diet-induced weight gain and boosted treadmill performance. In people the picture is thinner: MOTS-c rises in muscle with exercise, but no completed human trial has yet tested giving it as a drug. This page lays out what the studies actually measured.
What Is MOTS-c?
MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1 [1]. That makes it a mitochondrial-derived peptide — a bioactive peptide written into mitochondrial DNA rather than the nuclear genome, the same small family as humanin and the SHLPs. It is highly conserved across mammals, circulates in human plasma, and is detectable in skeletal muscle, where its levels shift with age, exercise, and metabolic state [2][5].
The founding 2015 paper established its central action: MOTS-c inhibits the folate cycle (one-carbon metabolism — the reactions that supply building blocks for new DNA) and de novo purine synthesis, which causes AICAR to pile up and activate AMPK (AMP-activated protein kinase, the enzyme a cell uses as its low-fuel sensor) [1]. Skeletal muscle is its primary target organ.
What does the MOTS-c peptide do?
It inhibits the folate cycle and de novo purine synthesis, raising AICAR (a small molecule that switches AMPK on) and activating AMPK to improve glucose handling [1]. Under metabolic stress it also translocates from the mitochondrion into the nucleus and helps regulate stress-response genes [3]. A 2024 study identified casein kinase 2 (CK2) — a constantly active signaling enzyme — as a direct binding target that carries some of its muscle and fat effects [11].
What is MOTS-c peptide used for?
MOTS-c is a research peptide studied for metabolic regulation, exercise and AMPK signaling, and aging biology [4]. In animal models it improved insulin sensitivity, prevented diet-induced obesity, and enhanced physical capacity; the human evidence to date is observational rather than interventional [1][2][12].
What the Research Suggests MOTS-c May Do
In the 2015 founding study, MOTS-c prevented high-fat-diet-induced obesity and both age-dependent and diet-induced insulin resistance in mice, with skeletal muscle as the primary target and AMPK as the downstream effector [1]. In aged mice, exogenous MOTS-c increased treadmill running capacity, grip strength, and gait — a result that held in young, middle-aged, and old animals [2]. A 2024 study showed it prevented skeletal-muscle atrophy and enhanced muscle glucose uptake by directly binding CK2 [11].
The human signal is narrower and observational. In a preliminary study, serum MOTS-c correlated positively with lower-body muscle strength but not with VO2max [6]. In healthy aging men, muscle MOTS-c expression rose with age and tracked myofiber composition [5]. A 2024 multicenter cohort even found circulating MOTS-c independently associated with a mortality and cardiovascular endpoint in hemodialysis patients [13]. These are associations, not outcomes from giving people the peptide — they show the body's own MOTS-c travels with health states, not that supplementing it changes them.
The pattern across the strongest findings is consistent: improved glucose handling, protection of muscle, and enhanced physical capacity, all converging on skeletal muscle and the AMPK axis [1][2][11]. That convergence is what makes the peptide interesting; the missing interventional human trials are what keep it a research compound rather than a therapy.
What are the potential benefits of MOTS-c?
In animal and cell studies, MOTS-c improved insulin sensitivity, prevented diet-induced obesity, enhanced physical capacity, and protected muscle [1][2][11]. Human data are observational — circulating MOTS-c is altered by exercise and metabolic state — so these findings describe what the peptide did in models, not established human benefits [12].
MOTS-c, Adiposity, and Metabolic Weight Regulation in Animal Models
MOTS-c's best-replicated metabolic effect is the prevention of fat gain rather than the reversal of existing weight. In the 2015 study, mice on a high-fat diet given MOTS-c were protected from diet-induced obesity and the insulin resistance that accompanies it; the AMPK pathway it activates is the same one that shifts cells toward glucose uptake and energy expenditure [1]. The 2023 reference review frames adipose thermogenesis and improved glucose handling as core to the metabolic story [4].
Does MOTS-c burn fat?
In mice, MOTS-c increased adipose thermogenesis and prevented diet-induced obesity rather than driving fat loss in already-lean animals [1][4]. No completed human fat-loss trial has confirmed a body-composition effect, so any "fat-burning" claim describes a rodent finding, not a human outcome [12].
Reading the literature honestly
Consumer interest in MOTS-c — for fat loss, longevity, and performance — runs well ahead of the clinical evidence. Every efficacy claim above comes from cell or animal work; the human record is observational biomarker data, not interventional outcomes [12]. A 2023 review frames the peptide's therapeutic potential across metabolic and aging indications while making the same point — the promise is real, the human trials are not yet done [9]. There is no validated human pharmacokinetics, so the rodent doses cannot be read across to people [12].
This digest exists to set that record straight, study by study. If you are new to it, start with what MOTS-c is; the MOTS-c exercise-mimetic research covers the physical-capacity findings in detail; MOTS-c dosage in the research literature walks through the doses and routes used in animals; the MOTS-c half-life and pharmacokinetics section explains why no human interval is established; and MOTS-c legal status and 503A access covers regulatory standing. For the underlying mechanism, see the underlying MOTS-c research.